Overview

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2031-03-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Phase:

PHASE3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

MYK-461